Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

HRD + BRCA wild-type

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related biomarkers:

‹

BRCA mutation (3)

BRCA mutation (3)

›

HRD + BRCA wild-type	Ovarian Cancer	HRD + BRCA wild-type	Ovarian Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
HRD + BRCA wild-type	Ovarian Cancer	HRD + BRCA wild-type	Ovarian Cancer	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2
HRD + BRCA wild-type	Ovarian Cancer	HRD + BRCA wild-type	Ovarian Cancer	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2
HRD + BRCA wild-type	Triple Negative Breast Cancer	HRD + BRCA wild-type	Triple Negative Breast Cancer	D19466 Sensitive: C3 – Early Trials D19466 Sensitive : C3	D19466 Sensitive: C3 – Early Trials D19466 Sensitive : C3
HRD + BRCA wild-type	Triple Negative Breast Cancer	HRD + BRCA wild-type	Triple Negative Breast Cancer	carboplatin Sensitive: C3 – Early Trials carboplatin Sensitive : C3	carboplatin Sensitive: C3 – Early Trials carboplatin Sensitive : C3
HRD + BRCA wild-type	Triple Negative Breast Cancer	HRD + BRCA wild-type	Triple Negative Breast Cancer	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3